- QMRO Home
- Blizard Institute
- Centre for Neuroscience, Surgery and Trauma
- Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Browse
Administrators only